NEW YORK (GenomeWeb) – Catalyst Pharmaceuticals has signed an agreement to use Biocept's Target Selector liquid biopsy platform to screen for cancer in patients enrolled in a clinical trial of its rare disease drug Firdapse (amifampridine phosphate).

Firdapse is currently approved in the EU to treat Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease often associated with malignancies such as small cell lung cancer. Catalyst holds the drug's North American rights.